Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1003 in ALK+ Advanced NSCLC
NCT03130881Phase 1Unknown
- Sponsor
- Beijing Pearl Biotechnology Co., Ltd.
- Start
- Nov 2016
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLB1003 in non-small cell lung cancer (NSCLC), sponsored by Beijing Pearl Biotechnology Co., Ltd. Primary endpoint: Number of Participants With Dose Limiting Toxicities at 18 months. Status: unknown.
02
Drugs
PLB1003
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03130881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130881.